Last updated: March 2026
Kisspeptin is the master upstream gatekeeper of human reproduction — the neuropeptide that fires before everything else. By activating GnRH neurons, it initiates the entire hormonal cascade from hypothalamus to pituitary to gonads. Now at the center of a revolution in IVF: same efficacy as hCG triggers, with a fraction of the hyperstimulation risk.
Kisspeptin sits at the very top of the reproductive hormone cascade — the earliest known activator of the HPG axis.
HPG = Hypothalamic-Pituitary-Gonadal. Kisspeptin disruption leads to complete reproductive failure (Kallmann-like phenotype).
The KISS1 gene encodes a 145-amino acid precursor protein (kisspeptin-145). This is cleaved into active fragments: kisspeptin-54 (the main circulating form), kisspeptin-14, kisspeptin-13, and kisspeptin-10 (the shortest, most potent per-molecule form). All share the C-terminal RF-amide motif required for KISS1R binding.
Kisspeptin binds to KISS1R — a Gq/11-coupled GPCR expressed on GnRH neurons. Receptor activation triggers phospholipase C → IP3/DAG → calcium mobilization → GnRH neuron depolarization and peptide release. Loss-of-function KISS1R mutations cause complete hypogonadotropic hypogonadism.
KNDy neurons (co-expressing Kisspeptin, Neurokinin B, and Dynorphin) in the arcuate nucleus generate the intrinsic GnRH pulse rhythm. Kisspeptin drives pulse initiation; dynorphin terminates pulses; NKB amplifies them. This circuit is the biological clock of reproduction.
Kisspeptin neurons are highly sensitive to sex steroid feedback. In females, kisspeptin neurons in the anteroventral periventricular nucleus (AVPV) mediate the positive feedback that generates the preovulatory LH surge — a unique feature absent in most other GnRH stimulators.
KISS1R is expressed beyond the hypothalamus — in limbic regions including the amygdala, hippocampus, and cortex. This supports kisspeptin's emerging role in sexual motivation and emotional processing, independent of its hormonal effects. fMRI studies confirm brain-level activity changes.
Unlike GnRH agonists (triptorelin, leuprolide) which cause receptor downregulation with continuous use, kisspeptin works upstream — it stimulates endogenous pulsatile GnRH release, maintaining physiologic GnRH receptor sensitivity. This is a critical pharmacological advantage.
The most clinically advanced kisspeptin application. A single IV dose can trigger final oocyte maturation — with dramatically lower OHSS risk than the standard hCG trigger.
Why the 28-minute half-life matters: Kisspeptin-54 is cleared rapidly from circulation. The LH surge it induces is self-limiting — the pituitary releases a surge and then returns to baseline. This mirrors the physiology of a natural LH surge far more closely than the sustained hCG signal, which is why the ovaries aren't chronically overstimulated.
Professor Waljit Dhillo and the Imperial College London endocrinology group have produced the defining body of human kisspeptin research over the past 15 years.
The Imperial Group (Prof. Waljit Dhillo, Dr. Ali Abbara, Dr. Alexander Comninos) has run more human kisspeptin trials than any other institution worldwide. Their work spans from the first proof-of-concept IV infusion studies in healthy volunteers to Phase 2 IVF trigger trials and the first fMRI studies of kisspeptin's brain effects.
Kisspeptin doesn't just act on the hypothalamus. fMRI research reveals it activates limbic circuits linked to sexual arousal and emotional bonding — independent of sex hormones.
Kisspeptin-54 IV infusion significantly enhanced amygdala activation in response to sexual stimuli in both men and women. The amygdala plays a central role in processing sexual cues, emotional salience, and social bonding behaviors.
Hippocampal activation increased with kisspeptin during emotional and romantic imagery tasks, suggesting a role in forming and retrieving emotionally-charged memories. This may underlie kisspeptin's association with pair bonding and attachment behavior in animal models.
The anterior insula — associated with interoception, social emotions, and empathy — showed significantly higher activation under kisspeptin. This is distinct from the hormonal effects and suggests kisspeptin may play a direct neuromodulatory role in interpersonal bonding.
Critically, the Comninos 2017 study found these fMRI effects were present even before sex steroid levels changed — confirming that kisspeptin directly modulates neural processing beyond its role as a hormonal trigger. KISS1R in limbic circuits is the likely mediator.
Clinical implication: These findings open the door to kisspeptin as a treatment for psychosexual disorders — hypothalamic amenorrhea with loss of libido, hypoactive sexual desire disorder, and potentially post-SSRI sexual dysfunction. Early-phase trials are exploring these applications.
Kisspeptin has distinct research profiles for males and females — fertility remains the primary clinical focus for both.
Single IV dose of kisspeptin-54 (9.6 nmol/kg) triggers final oocyte maturation 36–40 hours before egg retrieval. Especially valuable for high-risk IVF patients (PCOS, high AMH) where hCG triggers carry high OHSS risk. Represents the most clinically advanced indication.
IV kisspeptin-54 potently stimulates LH release in healthy men and men with hypothalamic hypogonadism. Imperial College data shows dose-dependent LH surges within minutes. Potential application in hypogonadotropic hypogonadism where the hypothalamic pulse generator is impaired.
Women with HA (loss of menstrual function due to energy deficit, stress, or overtraining) have impaired kisspeptin neuron activity. Pulsatile kisspeptin administration has been shown to restore GnRH pulsatility and LH secretion, potentially inducing ovulation without full gonadotropin therapy.
For men with hypogonadotropic hypogonadism who want to preserve fertility (vs TRT which suppresses sperm production), kisspeptin-based protocols could stimulate endogenous LH/FSH to maintain spermatogenesis. Research is early — no established clinical protocols exist.
Women with PCOS have dysregulated GnRH pulse frequency — too fast, driving LH dominance over FSH. Kisspeptin circuit dynamics may contribute to this dysfunction. Understanding how to normalize kisspeptin-neurokinin B-dynorphin signaling is an active PCOS research area.
Based on fMRI data showing limbic activation, kisspeptin is being studied for hypoactive sexual desire disorder (HSDD) in both men and women. The effect appears to be direct neuromodulation rather than via sex steroid levels — potentially opening a new class of sexual health treatments.
These are research and investigational protocols from published clinical trials. No standardized approved dosing exists.
| Application | Form | Route | Dose | Timing / Notes |
|---|---|---|---|---|
| IVF Trigger | Kisspeptin-54 | IV bolus | 9.6 nmol/kg (~1.4–2mg for 70kg) | Single dose 36–40h before egg retrieval. Optimal dose per Abbara et al. 2020. |
| LH Stimulation (Research) | Kisspeptin-54 | IV infusion | 1–6.4 nmol/kg/h | Dose-escalation research protocols. Duration varies (1–90 min infusions). Not for self-administration. |
| Hypogonadism Study | Kisspeptin-54 | IV bolus | 1.6–3.2 nmol/kg | Single diagnostic dose to assess hypothalamic-pituitary axis responsiveness in investigational settings. |
| SubQ (Investigational) | Kisspeptin-10 or -54 | Subcutaneous | Variable — no established dose | SubQ bioavailability lower than IV. KP-10 (kisspeptin-10) sometimes used. No human SubQ efficacy trials published as of 2026. |
| HA Restoration (Research) | Kisspeptin-54 | IV pulsatile | 0.4 nmol/kg pulses q90 min | Research protocol mimicking natural GnRH pulse frequency. Specialized infusion pump required. |
Forms in research: Kisspeptin-54 is the primary form studied in human IVF/fertility trials. Kisspeptin-10 (KP-10) is the most potent molar form and is more commonly seen in research-grade peptide markets, though human clinical efficacy data is limited vs KP-54. Both are IV or SubQ; oral administration is not bioavailable due to peptide degradation.
Kisspeptin has a favorable short-term safety profile in published Phase 1/2 trials. Long-term data in non-IVF settings is limited.
Currently most clinically relevant for fertility applications — particularly high-risk IVF patients. Other applications are investigational.
What the research actually shows — and what it doesn't.
Kisspeptin works within the same reproductive axis as these compounds. Understanding all of them gives the full picture.
Supplies for peptide research protocols
Affiliate links support MeetPeptide research at no extra cost to you.
This page is for educational and informational purposes only. Kisspeptin is an investigational compound and is not approved by the FDA or EMA for any indication as of 2026. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation. The clinical data cited reflects published peer-reviewed research conducted in supervised institutional settings — not protocols endorsed for self-administration. Always consult a qualified physician or reproductive endocrinologist before considering any fertility treatment. Cross-trial comparisons carry significant limitations — different patient populations, study designs, and endpoints make direct efficacy comparisons between kisspeptin and hCG approximate.